Research To Practice | Oncology Videos

Latest Episodes:

Prostate Cancer | Andrew J Armstrong, MD, ScM Mar 28, 2024

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Prostate Cancer | Faculty Presentation 2: Other Available and Emerging Therapeutic Approaches in Prostate Cancer — Andrew J Armstrong, MD, ScM

CME information and select publications

Prostate Cancer | Maha Hussain, MD, FACP, FASCO Mar 28, 2024

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Prostate Cancer | Faculty Presentation 1: Optimizing the Role of Hormonal Therapy and Novel Therapeutic Strategies for Patients with Prostate Cancer — Maha Hussain, MD, FACP, FASCO

CME information and select publications

Lymphoma | Andrew M Evens, DO, MBA, MSc Mar 27, 2024

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Lymphoma | Faculty Presentation 2: Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma — Andrew M Evens, DO, MBA, MSc

CME information and select publications

Lymphoma | Sonali M Smith, MD Mar 27, 2024

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Lymphoma | Faculty Presentation 1: Follicular and Mantle Cell Lymphoma — Sonali M Smith, MD

CME information and select publications

Lymphoma | Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Lymphoma Mar 27, 2024

Show notes

Featuring perspectives from Dr Andrew M Evens and Dr Sonali M Smith, including the following topics:

Introduction: CD3-Based Bispecific Antibodies and the General Medical Oncologist: Lymphomas, Multiple Myeloma … and Solid Tumors? (0:00)
Follicular and Mantle Cell Lymphoma (7:17)
Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma (30:10)

CME information and select publications

ER-Positive Metastatic Breast Cancer | Oncology Today with Dr Neil Love: Overcoming Endocrine Resistance in ER-Positive Metastatic Breast Cancer Mar 26, 2024

Show notes

Featuring perspectives from Dr Seth Wander, including the following topics:

Case: A woman in her mid-50s with ER-positive, PR-negative, HER2 IHC 1+ metastatic breast cancer (mBC), Recurrence Score® (RS) = 35 (0:00)
Mechanisms of resistance to antiestrogen therapy in HR-positive mBC (2:33)
Optimal approaches to biomarker assessment (15:37)
Case (continued): A woman in her mid-50s with ER-positive, PR-negative, HER2 IHC 1+ mBC, RS = 35 (18:27)
Case: A woman in her early 60s with de novo HR-positive, HER2-negative mBC with an ESR1 mutation after disease progression on first-line ribociclib/letrozole (20:22)
EMERALD — Phase III data guiding the use of elacestrant (21:39)
Emerging oral selective estrogen receptor degraders — camizestrant and imlunestrant (29:32)
Case (continued): A woman in her early 60s with de novo HR-positive, HER2-negative mBC with an ESR1 mutation after disease progression on first-line ribociclib/letrozole (45:44)
Case: A woman in her early 60s with HR-positive, HER2-negative mBC and a PIK3CA mutation who develops a new ESR1 mutation after disease progression on CDK4/6i and aromatase inhibitor (47:22)
CAPItello-291 — Phase III data guiding the use of capivasertib (48:52)
Case (continued): A woman in her early 60s with HR-positive, HER2-negative mBC and a PIK3CA mutation who develops a new ESR1 mutation after disease progression on CDK4/6i and aromatase inhibitor (52:41)
Additional promising antiestrogens — vepdegestrant and lasofoxifene (58:41)

CME information and select publications

Hepatobiliary Cancers | Consensus or Controversy? Immune Checkpoint Inhibitors in the Management of Hepatobiliary Cancers — A 2024 Post-ASCO Gastrointestinal Cancers Symposium Review Mar 21, 2024

Show notes

Featuring perspectives from Dr Robin (Katie) Kelley and Dr Mark Yarchoan, including the following topics:

Introduction: Interdisciplinary Management of Hepatocellular Carcinoma (HCC) in the Community (General Medical Oncology) Setting — Radiology, Hepatology, Pathology Support (0:00)
Potential Role of Anti-PD-1/PD-L1 Antibodies in the Care of Patients with Early- and Intermediate-Stage HCC — Dr Yarchoan (8:09)
HCC Rounds (22:07)
Tolerability and Other Practical Considerations with the Use of Immune Checkpoint Inhibitors for Advanced HCC and Biliary Tract Cancers (BTCs) — Dr Kelley (39:25)
Faculty Survey (49:19)
BTC Rounds (52:19)

CME information and select publications

Non-Small Cell Lung Cancer | Oncology Today with Dr Neil Love: Promising Therapeutic Strategies for Patients with Progressive Metastatic Non-Small Cell Lung Cancer Mar 20, 2024

Show notes

Featuring perspectives from Dr Melissa Johnson, including the following topics:

Role of biomarker testing in optimal selection of first-line therapy for patients with non-small cell lung cancer (NSCLC) (0:00)
Efficacy and safety with datopotamab deruxtecan for previously treated NSCLC (15:45)
Antitumor activity with and current status of CEACAM5-targeted therapy for relapsed NSCLC (30:24)
Evolution of drug development and clinical research (37:56)
Key findings with sacituzumab govitecan for NSCLC (41:59)
Telisotuzumab vedotin for patients with NSCLC and MET expression (48:44)
Recent findings with tumor treating fields for metastatic NSCLC after disease progression on platinum-based therapy (50:49)
Other novel antibody-drug conjugates under investigation for NSCLC (55:26)
Case: A woman in her mid 50s with recurrent extensive-stage small cell lung cancer who developed pneumonitis on ifinatamab deruxtecan (59:05)
Case: A woman in her early 60s with complete response to dose-reduced patritumab deruxtecan (1:00:15)

CME information and select publications

HER2-Positive and Triple-Negative Breast Cancer | Priyanka Sharma, MD Mar 15, 2024

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in HER2-Positive and Triple-Negative Breast Cancer | Faculty Presentation 2: Triple-Negative Breast Cancer — Priyanka Sharma, MD

CME information and select publications

HER2-Positive and Triple-Negative Breast Cancer | Ian E Krop, MD, PhD Mar 15, 2024

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in HER2-Positive and Triple-Negative Breast Cancer | Faculty Presentation 1: HER2-Positive Breast Cancer — Ian E Krop, MD, PhD

CME information and select publications